Loading...
Nuvalent, Inc.
NUVL•NASDAQ
Healthcare
Biotechnology
$81.41
$-0.67(-0.82%)
Nuvalent, Inc. (NUVL) Financial Performance & Income Statement Overview
Review Nuvalent, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-87.55%
↓ 87.55%
Net Income Growth
-106.59%
↓ 106.59%
Operating Cash Flow Growth
-85.55%
↓ 85.55%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-31.35%
↓ 31.35%
ROIC
-31.30%
↓ 31.30%
Nuvalent, Inc. (NUVL) Income Statement & Financial Overview
Review Nuvalent, Inc.'s (NUVL) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $69.42M | $60.55M | $49.17M | $38.63M |
| SG&A Expenses | $16.88M | $15.78M | $15.98M | $13.95M |
| Operating Expenses | $86.30M | $76.33M | $65.15M | $52.59M |
| Total Costs & Expenses | $86.30M | $76.33M | $65.15M | $52.59M |
| Interest Income | $13.05M | $8.63M | $8.15M | $8.49M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $8.49M |
| Depreciation & Amortization | $0.00 | $0.00 | $0.00 | $52.59M |
| EBITDA | -$86.30M | -$76.33M | -$65.15M | -$52.59M |
| EBITDA Ratio | ||||
| Operating Income | -$86.30M | -$76.33M | -$65.15M | -$52.59M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $11.71M | -$7.97M | $8.15M | $8.49M |
| Income Before Tax | -$74.59M | -$84.31M | -$57.00M | -$44.10M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $171000.00 | $40000.00 | $170000.00 | -$383000.00 |
| Net Income | -$74.76M | -$84.34M | -$57.17M | -$44.48M |
| Net Income Ratio | ||||
| EPS | -$1.05 | -$1.28 | -$0.88 | -$0.69 |
| Diluted EPS | -$1.05 | -$1.28 | -$0.88 | -$0.69 |
| Weighted Avg Shares Outstanding | $71.16M | $65.68M | $64.61M | $64.15M |
| Weighted Avg Shares Outstanding (Diluted) | $71.16M | $65.68M | $64.61M | $64.15M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan